Findings

What do systematic reviews say?

670 questions · 686 findings · 338 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 349 · 50.9%GRADE not reported 70 · 10.2%Very low 75 · 10.9%Low 75 · 10.9%Moderate 87 · 12.7%High 30 · 4.4%

Patisiran vs placebo

QoL · people with TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 225 participants
Low

Inotersen vs placebo

QoL · people with TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 172 participants
Low

Tafamidis vs placebo

QoL · people with early‐stage TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 125 participants
Very low

CDLQI Scores range from 0 to 30. Lower scores indicate better health‐related quality of life. Calculations are based on the change from baseline to week 12 in both groups · people with paediatric psoriasis

1 finding from 1 review

Anti‐TNF agents for paediatric psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 211 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

QoL · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 163 participants
GRADE not reported

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Ascorbic acid vs placebo

Health‐related quality of life (physical) · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 400 participants
Moderate

Eculizumab vs placebo

Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · patients with paroxysmal nocturnal hemoglobinuria

1 finding from 1 review

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Low

Physiotherapy and occupational therapy vs placebo

Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments Functional Independence Measure (total). Scale from: 0 to 126. Higher scores indicate less disability · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Very low

Indacaterol vs long‐acting beta2‐agonist alone

Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease

Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

1 finding from 1 review

Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
OR 1.07 [0.87, 1.32]
2 studies · 1520 participants
Moderate